Pre-Seed investment of €1.5 million was secured by En Carta Diagnostics, a Paris, France-based firm that creates quick point-of-care (POC) molecular diagnostic kits.
Investors
- CentraleSupélec Venture
- Undisclosed Angles contributing
Use of funds
The business plans to use the money to execute its go-to-market strategy and to build a diagnostic kit that would enable it to automatically diagnose Lyme illness in a matter of minutes.
Given that Lyme disease is now the most common vector-borne illness in the Northern Hemisphere (1.2 million cases yearly), the business is focusing on treating it as its initial application.
Early in 2025, En Carta plans to provide preclinical evidence.
About En Carta
En Carta, led by CEO Guillaume Horreard, offers a cost-effective cassette-based Point-of-Care diagnostic platform. It makes use of aptamers, which have a high affinity and specificity for binding to a predefined target. There is a vast array of applications that may be made possible by programming this “signature” to detect any genetic, pathogenic, or veterinary indication.